Flucytosine indications and usage: Difference between revisions
Ahmed Zaghw (talk | contribs) (Created page with "__NOTOC__ {{Flucytosine}} {{CMG}}; {{AE}} {{AZ}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ANCOBON (FLUCYTOSINE) CAPSULE [VALEANT PHARMACEU...") |
Ahmed Zaghw (talk | contribs) No edit summary |
||
Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}} | ||
==Indications and Usage== | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ANCOBON (FLUCYTOSINE) CAPSULE [VALEANT PHARMACEUTICALS NORTH AMERICA LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aea0df00-a88c-4a16-abcf-750f3ff2004e | publisher = | date = | accessdate = }}</ref> | Ancobon is indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus. | ||
'''[[Candida]]''': Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. | |||
'''[[Cryptococcus]]''': Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. | |||
Ancobon should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Ancobon.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ANCOBON (FLUCYTOSINE) CAPSULE [VALEANT PHARMACEUTICALS NORTH AMERICA LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aea0df00-a88c-4a16-abcf-750f3ff2004e | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== |
Latest revision as of 18:58, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Indications and Usage
Ancobon is indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus.
Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine.
Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported.
Ancobon should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Ancobon.[1]
References
Adapted from the FDA Package Insert.